Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers

Conen, Silke; Theunissen, Eef L.; Oers, Anita C M Van; Valiente, Román; Ramaekers, Johannes G.

doi:10.1177/0269881110382467

Cited by 53 publications

(31 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After 8 days of treatment with hydroxizine 50 mg driving performance was still impaired, but to a lesser extent (Conen et al 2010).…”

Section: First Generation Antihistaminesmentioning

confidence: 88%

See 1 more Smart Citation

Effects of Medicinal Drugs on Fitness to Drive

Theunissen¹,

Kuypers²,

Vermeeren³

et al. 2014

Handbook of Forensic Medicine

View full text Add to dashboard Cite

“…After 8 days of treatment with hydroxizine 50 mg driving performance was still impaired, but to a lesser extent (Conen et al 2010).…”

Section: First Generation Antihistaminesmentioning

confidence: 88%

“…The effects of rupatadine in its therapeutic dose of 10 mg (Vuurman et al 2007) were also comparable to those of placebo treatment. Bilastine was tested in 20 and 40 mg doses, both after acute dosing and repeated doses, and was found not to cause driving impairment in any of these dosing conditions (Conen et al 2010).…”

Section: Second Generation Antihistaminesmentioning

confidence: 99%

Effects of Medicinal Drugs on Fitness to Drive

Theunissen¹,

Kuypers²,

Vermeeren³

et al. 2014

Handbook of Forensic Medicine

View full text Add to dashboard Cite

“…Similar findings have been reported before. 1,33,56 It underscores the notion that users of hydroxyzine should receive explicit warnings about these drugs' deleterious effects on cognitive performance regardless of time of dosing.…”

Section: Discussionmentioning

confidence: 99%

Short-Term Effects of Morning Versus Evening Dose of Hydroxyzine 50 mg on Cognition in Healthy Volunteers

Conen

Theunissen²,

Vermeeren³

et al. 2011

Journal of Clinical Psychopharmacology

Self Cite

View full text Add to dashboard Cite

It is well known that the sedative properties of antihistamines can differ considerably between individual drugs. Several factors have been suggested to determine the presence, absence, and/or magnitude of sedation by antihistamines. Research has suggested that the sedative effects caused by central H1 blockade partly depend on the availability of histamine competing for the same receptor and that this competition is affected by a mechanism related to sleep. Consequently, the present study was designed to compare the effects of evening and morning doses of the first-generation antihistamine hydroxyzine on cognition. It was expected that the sedative effect of hydroxyzine would be apparent in the evening after an evening dose but would be smaller in the morning after a morning dose owing to the greater release of histamine shortly after awakening. Eighteen participants (9 females) participated in a placebo-controlled, randomized, double-blind 3-way crossover design. Performance was assessed using several psychomotor tests: that is, divided attention task, critical tracking task, stop signal task, the attention network test, and the experimental attention switch task. Results demonstrated that evening doses of hydroxyzine impaired performance on the divided attention and the attention network test. Impairment after morning doses was generally larger in magnitude and affected performance measures in all tasks. It is concluded that hydroxyzine-induced impairment at tmax is more prominent after morning doses compared with evening doses and that the present study could not present direct evidence to substantiate the hypothesis that histamine availability inversely affects the magnitude of antihistamine impairment.

show abstract

“…None of the conducted clinical trials showed any influence of bilastine on the morphology of the ECG signal and QTc interval. Thus, it could be stated that the cardiovascular safety of bilastine is very high, and the influence of the drug on morphology of the ECG signal and cardiac muscle repolarization is the same as that of placebo [10,15,[32][33][34][35][36][37][38][39][40][41][42][43][44].…”

Section: Cardiovascular Safety Of Antihistaminesmentioning

confidence: 99%

The role and choice criteria of antihistamines in allergy management – Expert opinion

Kuna

Jurkiewicz

Czarnecka‐Operacz

et al. 2017

Alergologia Polska - Polish Journal of Allergology

View full text Add to dashboard Cite

A b s t r a c tAllergic diseases are the most common chronic conditions lasting throughout the patient's life. They not only cause significant deterioration in the quality of life of patients but also lead to significant absenteeism and reduced productivity, resulting in very high costs for society. Effective and safe treatment of allergic diseases is therefore one of the main challenges for public health and should be carried out by all the specialists in family medicine, internists and paediatricians in collaboration with allergists, otorhinolaryngologists and dermatologists. Antihistamines are most commonly used in the treatment of allergies. Several dozen drugs are available on the pharmaceutical market, and their generic forms are advertised widely as very effective drugs for the treatment of allergic diseases. What is the truth? What are the data from clinical trials and observational studies? Are all drugs equally effective and safe for the patient? According to a panel of experts representing various fields of medicine, inappropriate treatment of allergies can be very risky for patients, and seemingly equally acting medications may differ greatly. Therefore, a panel of experts gathered the latest data from the entire scientific literature and analysed the latest standards and recommendations prepared by scientific societies. This paper provides a summary of these studies and highlights the importance for the patient of the proper choice of drug to treat his allergies.Key words: antihistamines, bilastin, allergic rhinitis, urticaria, allergy. Which antihistamines should be chosen according to current standards and recommendations?In the last few decades the incidence of allergic diseases has grown to epidemic status. According to the current data, more than 600 million people suffer from allergic rhinitis worldwide, approximately 25% of them in Europe. In the ECAP trial (Epidemiology of Allergic Diseases in Poland) as many as 30% of respondents reported allergic rhinitis, less than 7% mentioned urticaria, but over 40% of patients had positive skin tests with common inhaled allergens (e.g. plant pollen, dust mites, mould and animal hair). Despite this huge number of patients, these data are frequently underestimated, since allergic diseases are generally believed to be trivial and non-hazardous. However, it has already been proven that allergic rhinitis, asthma and urticaria are associated with a significant socioeconomic burden all over the world -regardless of region, development level and financial status. The total cost of allergic diseases brings both reduced quality of life and also direct costs of drugs and health services as well as indirect social costs such as the absence from work; it also decreases productivity and concentration and generates learning disorders and

show abstract

Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers

Cited by 53 publications

References 26 publications

Effects of Medicinal Drugs on Fitness to Drive

Effects of Medicinal Drugs on Fitness to Drive

Short-Term Effects of Morning Versus Evening Dose of Hydroxyzine 50 mg on Cognition in Healthy Volunteers

The role and choice criteria of antihistamines in allergy management – Expert opinion

Contact Info

Product

Resources

About